These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37046687)

  • 41. Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery.
    Knipper S; Lischewski F; Koehler D; Eiber M; van Leeuwen FWB; de Barros H; Berrens AC; Zuur L; van Leeuwen PJ; van der Poel H; Ambrosini F; Falkenbach F; Budäus L; Steuber T; Graefen M; Tennstedt P; Gschwend JE; Horn T; Heck MM; Maurer T
    Eur Urol Oncol; 2024 May; ():. PubMed ID: 38729805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.
    Cao Y; Sutera P; Silva Mendes W; Yousefi B; Hrinivich T; Deek M; Phillips R; Song D; Kiess A; Cem Guler O; Torun N; Reyhan M; Sawant A; Marchionni L; Simone NL; Tran P; Onal C; Ren L
    Radiother Oncol; 2024 Oct; 199():110443. PubMed ID: 39094629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
    Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis.
    Francolini G; Garlatti P; Di Cataldo V; Triggiani L; Simoni N; Detti B; Lorenzetti V; Colombo F; Morelli V; Ganovelli M; Caprara L; Orsatti C; Burchini L; Frosini G; Bertini N; Loi M; Simontacchi G; Greto D; Desideri I; Meattini I; Livi L
    Radiol Med; 2023 Nov; 128(11):1423-1428. PubMed ID: 37597125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
    J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of non-regional lymph node metastases accurately revealed on
    Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
    EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.
    Alberto M; Yim A; Papa N; Siva S; Ischia J; Touijer K; Eastham JA; Bolton D; Perera M
    Front Oncol; 2022; 12():929444. PubMed ID: 36059632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
    Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
    Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
    Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a?
    Chopade P; Maitre P; David S; Panigrahi G; Singh P; Phurailatpam R; Murthy V
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):711-717. PubMed ID: 35870708
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Mesci A; Ahmadi E; Ali A; Gouran-Savadkoohi M; Evelyn Tsakiridis E; Biziotis OD; Chow T; Kapoor A; Sur M; Steinberg GR; Liu S; Zukotynski K; Tsakiridis T
    Clin Transl Radiat Oncol; 2023 Mar; 39():100583. PubMed ID: 36713978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.
    Schmidt-Hegemann NS; Kroeze SGC; Henkenberens C; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Müller AC; Grosu AL; Combs SE; Christiansen H; Guckenberger M; Belka C
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1852-1863. PubMed ID: 32002591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
    Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Deandreis D; Guarneri A; Ceci F; Lillaz B; Bartoncini S; Oderda M; Nicolotti DG; Pilati E; Passera R; Zitella A; Bellò M; Parise R; Carlevato R; Ricardi U; Gontero P
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2804-2815. PubMed ID: 32314028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.